Medical therapy of malignant nerve pain. A randomised double-blind explanatory trial with naproxen versus slow-release morphine

1994 ◽  
Vol 30 (9) ◽  
pp. 1244-1250 ◽  
Author(s):  
P.L.I Dellemijn ◽  
H.B.C Verbiest ◽  
J.J van Vliet ◽  
P.J Roos ◽  
C.J Vecht
Keyword(s):  
Medical Therapy ◽  
Slow Release ◽  
Double Blind ◽  
Explanatory Trial

Once-Daily Treatment for Mixed Anxiety/Depressive States: A Comparison of Slow Release Amitriptyline and Fluphenazine with Nortriptyline

1977 ◽  
Vol 5 (2) ◽  
pp. 109-113 ◽  
Author(s):  
R V Magnus ◽  
A A Schiff
Keyword(s):  
Side Effects ◽  
Sustained Release ◽  
Slow Release ◽  
Anxiolytic Effect ◽  
Daily Treatment ◽  
Dry Mouth ◽  
Double Blind ◽  
Once Daily ◽  
Therapeutic Advantage ◽  
Depressive States

Patients suffering from mixed anxiety/depressive states referred to a psychiatric out-patient clinic completed a four week course of either a once-daily tablet of 30 mg nortriptyline with 1· 5 mg fluphenazine, or a sustained release capsule of 50 mg amitriptyline once daily, on a double-blind basis. Depression improved satisfactorily on either treatment, but there was a greater reduction of anxiety on fluphenazine/nortriptyline. Drowsiness, however, occurred more frequently among the patients on amitriptyline, suggesting the sedative properties of this drug did not substitute adequately for a specific anxiolytic effect. Dry mouth was also noticeably more frequent with amitriptyline. As might be expected on pharmacokinetic and physiological grounds, the results suggest that the sustained release characteristics of the amitriptyline preparation lead to a maximization of side-effects during the day without conferring any therapeutic advantage.

PHYSIOLOGICAL EFFECTS OF SLOW RELEASE POTASSIUM PHOSPHATE FOR ABSORPTIVE HYPERCALCIURIA: A RANDOMIZED DOUBLE-BLIND TRIAL

1998 ◽  
Vol 160 (3 Part 1) ◽  
pp. 664-668 ◽  
Author(s):  
NEIL A. BRESLAU ◽  
HOWARD J. HELLER ◽  
ALFREDO A. REZA-ALBARRAN ◽  
CHARLES Y.C. PAK
Keyword(s):  
Slow Release ◽  
Potassium Phosphate ◽  
Physiological Effects ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Absorptive Hypercalciuria

No Effect Of Persantin On Platelet Aggregation And Plasma βTg Levels In Healthy Volunteers

1981 ◽  
Author(s):  
A W A Lensing ◽  
A Sturk ◽  
J W ten Cate
Keyword(s):  
Side Effects ◽  
Healthy Volunteers ◽  
Cerebrovascular Accident ◽  
Slow Release ◽  
Double Blind Study ◽  
Prolonged Administration ◽  
Double Blind ◽  
Normal Limits ◽  
Induced Aggregation ◽  
Release Form

Previous studies from our laboratory revealed no effect of aspirin on plasma βTG levels in healthy volunteers as well as in patients with cerebrovascular accident. This double blind study was undertaken to investigate the effect of prolonged administration of Persantin. Two groups of 10 volunteers each received 4×100 mg Persantin or 2×200 mg daily in slow release form for 21 days. Platelet studies were performed prior to- and once every week during the trial. The volunteers refrained from smoking and were not on oral contraceptives or other drugs. No effect was observed on ADP (1 μ M f.c.) or collagen induced aggregation. All βTG plasma levels were within normal limits i.e. below 60/ml of plasma. No tendency of decreasing levels was observed. Side effects were significantly more observed in the volunteers on slow release Persantin (Mean Whitney Test α < 0.025). Side effects included sensations of a dry mouth and thirst, headache and di2Lzyness.

Classic Migraine: Effective Prophylaxis with Metoprolol

Cephalalgia ◽  
1987 ◽  
Vol 7 (4) ◽  
pp. 231-238 ◽  
Author(s):  
P Kangasniemi ◽  
AR Andersen ◽  
PG Andersson ◽  
NE Gilhus ◽  
C Hedman ◽  
...  
Keyword(s):  
Slow Release ◽  
Global Rating ◽  
Prophylactic Effect ◽  
Double Blind ◽  
Once Daily ◽  
Total Frequency ◽  
Effective Prophylaxis ◽  
Better Than

Metoprolol slow-release tablets (Durules®), 200 mg, given once daily in the morning were compared with placebo in the prophylaxis of classic migraine. The trial comprised eight Scandinavian neurologic centres and was designed as a double-blind cross-over study with 4 weeks' run-in, four weeks washout, and 8 weeks of either treatment. Seventy-seven patients with two to eight migraine attacks per month were entered in the trial, and 73 completed it. A total of 1119 attacks with aura symptoms and 374 without were recorded. Metoprolol was significantly better than placebo with regard to the total frequency of attacks (1.8 versus 2.5 attacks/4 weeks), mean duration of attacks (6.0 versus 8.0 h/attack), mean global rating, and consumption of analgesics per attack: Similar differences could be shown for attacks with aura symptoms alone, except for the duration of attacks. Metoprolol is the first drug for which a prophylactic effect in classic migraine has been convincingly demonstrated.

A multi-center, double-blind study on slow-release bromocriptine in the treatment of Parkinson's disease

Neurology ◽  
1991 ◽  
Vol 41 (10) ◽  
pp. 1598-1598 ◽  
Author(s):  
T. Mannen ◽  
Y. Mizuno ◽  
M. Iwata ◽  
I. Goto ◽  
I. Kanazawa ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Slow Release ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document